ARS Pharmaceuticals (SPRY) Other Gross PP&E Adjustments (2020 - 2026)
ARS Pharmaceuticals recorded quarterly Other Gross PP&E Adjustments of -$828000.0 in Q1 2026, up 75.04% quarter-over-quarter from -$3.3 million in Q4 2025, and down 80.0% year-over-year from -$4.1 million in Q1 2025.
ARS Pharmaceuticals' Other Gross PP&E Adjustments history runs 7 years deep, the most recent figure standing at -$828000.0 for Q1 2026.
- In Q1 2026, Other Gross PP&E Adjustments fell 80.0% year-over-year to -$828000.0; the TTM figure through Mar 2026 stood at -$4.1 million (down 801.09% YoY), while the FY2025 annual figure was -$3.3 million, down 142.12% from the prior year.
- Other Gross PP&E Adjustments came in at -$828000.0 for Q1 2026 at ARS Pharmaceuticals, up from -$3.3 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $41000.0 in Q1 2024 to a low of -$5.5 million in Q1 2022.
- A 5-year average of -$1.5 million and a median of -$1.2 million in 2023 frame the typical range for Other Gross PP&E Adjustments.
- On a YoY basis, Other Gross PP&E Adjustments climbed as much as 117.3% in 2024 and fell as far as 4213.79% in 2024.
- ARS Pharmaceuticals' Other Gross PP&E Adjustments stood at -$2.3 million in 2022, then soared by 50.66% to -$1.2 million in 2023, then decreased by 18.31% to -$1.4 million in 2024, then tumbled by 142.12% to -$3.3 million in 2025, then jumped by 75.04% to -$828000.0 in 2026.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered -$828000.0, -$3.3 million, and -$1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -189.30 Mn |
| 10 | ARS Pharmaceuticals | 900.62 Mn | 699.65 Mn | - | -828,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -828,000.00 |
| Mar 31, 2026 | -828,000.00 |
| Dec 31, 2025 | -3.32 Mn |
| Dec 31, 2025 | -3.32 Mn |
| Sep 30, 2025 | -1.68 Mn |
| Sep 30, 2025 | -1.68 Mn |
| Jun 30, 2025 | -2.04 Mn |
| Jun 30, 2025 | -2.04 Mn |
| Mar 31, 2025 | -460,000.00 |
| Mar 31, 2025 | -460,000.00 |
| Dec 31, 2024 | -1.37 Mn |
| Dec 31, 2024 | -1.37 Mn |
| Sep 30, 2024 | -1.48 Mn |
| Sep 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | -587,000.00 |
| Jun 30, 2024 | -587,000.00 |
| Mar 31, 2024 | 41,000.00 |
| Mar 31, 2024 | 41,000.00 |
| Dec 31, 2023 | -1.16 Mn |
| Dec 31, 2023 | -1.16 Mn |
| Sep 30, 2023 | -29,000.00 |
| Sep 30, 2023 | -29,000.00 |
| Jun 30, 2023 | -409,000.00 |
| Jun 30, 2023 | -409,000.00 |
| Mar 31, 2023 | -237,000.00 |
| Mar 31, 2023 | -237,000.00 |
| Dec 31, 2022 | -2.35 Mn |
| Dec 31, 2022 | -2.35 Mn |
| Sep 30, 2022 | -598,000.00 |
| Sep 30, 2022 | -598,000.00 |
| Jun 30, 2022 | -4.48 Mn |
| Jun 30, 2022 | -4.48 Mn |
| Mar 31, 2022 | -5.53 Mn |
| Mar 31, 2022 | -5.53 Mn |
| Dec 31, 2021 | -598,000.00 |
| Dec 31, 2021 | -598,000.00 |
| Sep 30, 2021 | -5.63 Mn |
| Sep 30, 2021 | -5.63 Mn |
| Jun 30, 2021 | -2.56 Mn |
| Jun 30, 2021 | -2.56 Mn |
| Mar 31, 2021 | -1.90 Mn |
| Mar 31, 2021 | -1.90 Mn |
| Dec 31, 2020 | 909,000.00 |
| Dec 31, 2020 | 909,000.00 |